Traws Pharma, Inc.TRAWNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank92
3Y CAGR+38.6%
5Y CAGR+28.6%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
+38.6%/yr
Annual compound
5Y CAGR
+28.6%/yr
Recent acceleration
Percentile
P92
Near historical high
vs 5Y Ago
3.5x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
202435.13%
20237.66%
2022-10.38%
202113.20%
2020-0.23%
201910.01%
20182.44%
2017-18.47%
2016-3.21%
2015-36.10%